San Diego, CA (October 25, 2018) -- The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2018 October 23-October 28 at the San Diego Convention Center.
Effect of Linagliptin on Kidney and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Kidney Disease: CARMELINA® .
In the multicenter, open-label, blinded endpoint, controlled trial, 2141 hemodialysis patients receiving erythropoiesis-stimulating agents were randomly assigned to a proactive, high-dose IV iron regimen or a reactive, low-dose IV iron regimen. "Patients receiving haemodialysis usually require Erythropoiesis Stimulating Agents--ESAs--to treat their anaemia. High doses of ESAs are potentially harmful, so we try to use low doses and enhance the patient's response by adding IV iron. Over recent years we have tended to give more iron and less ESAs, but the optimal balance between these therapies is not known," explained co-author David Wheeler, MBChB, MD, FRCP. "The PIVOTAL trial investigated whether giving higher doses of IV iron could be harmful, as suggested by previous observational studies. As compared to a lower dose, we found no evidence of harm when using a higher dose of IV iron and were able to reduce ESA doses and blood transfusions. A high dose iron, low dose ESA strategy could provide a safer approach to treating anaemia in haemodialysis patients and needs to be further evaluated in larger studies."
High-Dose versus Low-Dose Intravenous Iron Therapy in Hemodialysis: The PIVOTAL Trial
Safety and Effectiveness of Bexagliflozin in Type 2 Diabetes Mellitus and Stage 3a/3b Chronic Kidney Disease, a Phase III Randomized Clinical Trial
Effect of a Restrictive Versus Liberal Approach to Red Blood Cell Transfusion on Acute Kidney Injury in Patients Undergoing Cardiac Surgery
Interventions to Reduce Early Dialysis Initiation in Canada: A Cluster Randomized Trial
Comparative Efficacy of Therapies for Depression for Patients Undergoing Hemodialysis
###
ASN Kidney Week 2018, the largest nephrology meeting of its kind, will provide a forum for more than 13,000 professionals to discuss the latest findings in kidney health research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2018 will take place October 23 - October 28 at the San Diego Convention Center.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 131 countries. For more information, please visit http://www.asn-online.org .